These two companies are going after the same target, but which one should you bet on today?
News & Analysis: Madrigal Pharmaceuticals, Inc.
They have one big thing in common: great growth prospects.
These companies are developing drugs that target the one of the biggest threats from the obesity epidemic.
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
Which of these NASH-oriented biotechs is the better buy?
A new year and reasons to remain hopeful for these three biotechs are around the corner.
Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.
Madrigal's stock continued to cool off last month, but another rally could be close at hand.
Which stock wins in a matchup between these biotechs hoping for success with promising NASH drugs?
Solid phase 2 data has investors excited about the biotech's future.